Sign in

Gastric and oesophageal cancer: trials that stopped early

Trials on gastric and oesophageal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

131 stopped trials give a reason in the registry, latest registry update first. 5 more give no reason and are not listed.

  1. Terminated

    Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

    Reason given in the registry

    “R\&d strategy adjustment”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Aug 2025.

    Ended
    Apr 2024
    Phase
    Phase 2/3
    Run by
    Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    Registry record
    NCT05149807
  2. Withdrawn

    A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

    Reason given in the registry

    “Corporate business decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Jul 2025.

    Phase
    Phase 1/2
    Run by
    Artiva Biotherapeutics, Inc.
    Registry record
    NCT05678205
  3. Terminated

    89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

    Reason given in the registry

    “Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic component in the study design.”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Jul 2025.

    Ended
    May 2025
    Phase
    Phase 2
    Run by
    Telix Pharmaceuticals (Innovations) Pty Ltd
    Registry record
    NCT05563272
  4. Terminated

    FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

    Reason given in the registry

    “Business decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 Jun 2025.

    Ended
    Oct 2024
    Phase
    Phase 1
    Run by
    POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
    Registry record
    NCT05432193
  5. Terminated

    Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

    Reason given in the registry

    “Due to modification of company strategy.”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Jun 2025.

    Ended
    Feb 2024
    Phase
    Phase 2
    Run by
    BeiGene
    Registry record
    NCT05461794
  6. Terminated

    TAC T-cells for the Treatment of HER2-positive Solid Tumors

    Reason given in the registry

    “Study terminated by Sponsor for commercial reasons”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 Jun 2025.

    Ended
    Mar 2024
    Phase
    Phase 1/2
    Run by
    Triumvira Immunologics, Inc.
    Registry record
    NCT04727151
  7. Withdrawn

    Defining Musical Toxicity and Its Effect on Patient Well-being

    Reason given in the registry

    “Resident working with study left institution”

    Quoted unchanged from ClinicalTrials.gov; record updated 4 Jun 2025.

    Ended
    May 2025
    Run by
    Mayo Clinic
    Registry record
    NCT06494046
  8. Terminated

    Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

    Reason given in the registry

    “Study termination was based on strategic considerations and not due to specific safety reasons or a request from a regulatory authority.”

    Quoted unchanged from ClinicalTrials.gov; record updated 28 May 2025.

    Ended
    Dec 2024
    Phase
    Phase 1
    Run by
    Pfizer
    Registry record
    NCT04152018
  9. Terminated

    Transnasal Esophagoscopy (TNE) Esophageal Cancer Screening

    Reason given in the registry

    “Transnasal Esophagoscopy (TNE) scope is no longer manufactured so the study is unable to be continued.”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 May 2025.

    Ended
    Mar 2025
    Run by
    University of Illinois Chicago
    Registry record
    NCT05480891
  10. Terminated

    A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)

    Reason given in the registry

    “Study was discontinued because of slow enrollment and organizational priorities and not because of any findings related to safety or efficacy.”

    Quoted unchanged from ClinicalTrials.gov; record updated 11 May 2025.

    Ended
    Apr 2024
    Phase
    Phase 2
    Run by
    Imugene Limited
    Registry record
    NCT05311176
  11. Terminated

    Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

    Reason given in the registry

    “Study terminated by sponsor”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 May 2025.

    Ended
    Aug 2024
    Phase
    Phase 1/2
    Run by
    Hutchmed
    Registry record
    NCT04579757
  12. Terminated

    Early IntraVenous Administration of Nutritional Support

    Reason given in the registry

    “Changes in anticancer treatment protocols which limit recruitment”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 May 2025.

    Ended
    Jul 2024
    Run by
    Fondazione IRCCS Policlinico San Matteo di Pavia
    Registry record
    NCT03949907
  13. Suspended

    Acetic Acid for the Detection of Esophageal Neoplasms

    Reason given in the registry

    “not enough patients enrolled”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Apr 2025.

    Ended
    May 2025
    Run by
    Coordinación de Investigación en Salud, Mexico
    Registry record
    NCT04054713
  14. Withdrawn

    Study of OB-002 in Patients With Refractory Metastatic Cancer

    Reason given in the registry

    “study terminated due to changes in the drug development plan”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Apr 2025.

    Ended
    Aug 2025
    Phase
    Phase 1
    Run by
    Orion Biotechnology Polska Sp. z o.o.
    Registry record
    NCT05940844
  15. Terminated

    Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

    Reason given in the registry

    “Business decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Apr 2025.

    Ended
    Feb 2024
    Phase
    Phase 2
    Run by
    Elevation Oncology
    Registry record
    NCT04383210
  16. Terminated

    A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

    Reason given in the registry

    “Early discontinuation based on strategic sponsor decision not driven by any safety concerns.”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Apr 2025.

    Ended
    Oct 2024
    Phase
    Phase 1/2
    Run by
    Kymab Limited
    Registry record
    NCT03829501
  17. Terminated

    Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC

    Reason given in the registry

    “Sponsor Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Mar 2025.

    Ended
    Jan 2025
    Phase
    Phase 1
    Run by
    Viracta Therapeutics, Inc.
    Registry record
    NCT05166577
  18. Terminated

    A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

    Reason given in the registry

    “Study closed due to portfolio prioritization”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Mar 2025.

    Ended
    Nov 2023
    Phase
    Phase 2
    Run by
    Seagen Inc.
    Registry record
    NCT04032704
  19. Terminated

    Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma

    Reason given in the registry

    “Several clinical trials had showed that anti-PD-1 agents combined with chemotherapy as neoadjuvant treatment could increase pCR rate in 2024. In order to protect the interest of patients, this trial was stopted.”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 Feb 2025.

    Ended
    Nov 2024
    Phase
    Phase 2
    Run by
    Peking University
    Registry record
    NCT04804696
  20. Terminated

    Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients

    Reason given in the registry

    “slow accrual”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Feb 2025.

    Ended
    Oct 2024
    Phase
    Early phase 1
    Run by
    Mayo Clinic
    Registry record
    NCT04213794
  21. Suspended

    AN0025 and Chemoradiotherapy Combination in Esophageal Cancer

    Reason given in the registry

    “The study is not stopped but the enrollment is suspended until a further decision from sponsor.”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Feb 2025.

    Ended
    Dec 2025
    Phase
    Phase 1
    Run by
    Adlai Nortye Biopharma Co., Ltd.
    Registry record
    NCT05191667
  22. Terminated

    A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

    Reason given in the registry

    “Study closed due to portfolio prioritization”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Feb 2025.

    Ended
    Dec 2023
    Phase
    Phase 1
    Run by
    Seagen Inc.
    Registry record
    NCT04254107
  23. Terminated

    A Study of SGN-ALPV in Advanced Solid Tumors

    Reason given in the registry

    “Study closed due to portfolio prioritization”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Feb 2025.

    Ended
    Dec 2023
    Phase
    Phase 1
    Run by
    Seagen Inc.
    Registry record
    NCT05229900
  24. Terminated

    A Study of SGN-STNV in Advanced Solid Tumors

    Reason given in the registry

    “Study closed due to portfolio prioritization”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 Feb 2025.

    Ended
    Mar 2024
    Phase
    Phase 1
    Run by
    Seagen Inc.
    Registry record
    NCT04665921
  25. Withdrawn

    Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers

    Reason given in the registry

    “PI Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 Feb 2025.

    Ended
    Dec 2025
    Phase
    Phase 1
    Run by
    Ohio State University Comprehensive Cancer Center
    Registry record
    NCT05296005
  26. Withdrawn

    Molecular Analysis of Gastric and OEsophageal Cancers STudy

    Reason given in the registry

    “Never opened to recruitment due to lack of funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 Feb 2025.

    Run by
    Royal Marsden NHS Foundation Trust
    Registry record
    NCT06702384
  27. Withdrawn

    Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

    Reason given in the registry

    “Determined that enrollment would be limited due to the change in care setting.”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Jan 2025.

    Phase
    Phase 1
    Run by
    GC Cell Corporation
    Registry record
    NCT06341647
  28. Terminated

    Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

    Reason given in the registry

    “Study was terminated due to strategic considerations and not due to safety.”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Jan 2025.

    Ended
    Nov 2023
    Phase
    Phase 1
    Run by
    Pfizer
    Registry record
    NCT04171141
  29. Terminated

    Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer

    Reason given in the registry

    “Poor accrual and funding sponsor declared bankruptcy.”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Jan 2025.

    Ended
    Nov 2024
    Phase
    Phase 2
    Run by
    Washington University School of Medicine
    Registry record
    NCT04162665
  30. Terminated

    Oral AMXT 1501 Dicaprate in Combination With IV DFMO

    Reason given in the registry

    “Required re-formulation of DFMO from IV to capsule to maintain safety”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Dec 2024.

    Ended
    Dec 2024
    Phase
    Phase 1/2
    Run by
    Aminex Therapeutics, Inc.
    Registry record
    NCT05500508

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.